GLP-1 goliath updates demand for top weight loss drug
Novo Nordisk reported Q3 2025 earnings on November 5, showing continued strong demand for its weight-loss drug Wegovy,…
Eli Lilly says weight-loss pill a candidate for speedy approval under new US program
By Mrinalika Roy and Patrick Wingrove (Reuters) -Eli Lilly said on Thursday its experimental weight-loss pill met most…
Trump’s $150 Ozempic? Oz cautions it’s not a done deal, but patients and doctors say it could be a gamechanger
Janet McCaskill was on vacation in Arizona with her husband and best friend when she heard that President…
50 European corporates backing startups on the path to growth, innovation, and global impact
Across Europe, big companies are becoming strong backers of startup innovation, and corporate venturing is widely used as…
Ozempic maker urges Ottawa to shut down online drug sales to Americans
OTTAWA — Novo Nordisk, the Danish drug company that makes Ozempic and Wegovy, wants the Canadian government to…
GLP-1 Weight-Loss Pills Could Transform Treatment
A new era of weight-loss treatment could soon trade needles for pills. Drugmakers behind GLP-1 injections like Wegovy…
How the ‘Ozempic effect’ is reshaping the global economy
Michael Siluk/Alamy The new wave of weight-loss drugs has taken the world by storm. From Novo Nordisk’s Ozempic…
Wegovy And Zepbound Cost Effective But They Could Break Drug Budgets
The Institute for Clinical and Economic Review (ICER) on Tuesday released a Draft Evidence Report assessing the comparative…
How a change in FDA guidance might revolutionise MASH drug development
Transformative new shifts have taken place in the last month in the metabolic dysfunction-associated steatohepatitis (MASH) therapy space,…
Pricing group says weight-loss drugs becoming more cost-effective
By Deena Beasley (Reuters) -An influential drug pricing watchdog on Tuesday said popular GLP-1 weight-loss injections have become…
European stock markets are up, Novo Nordisk is among the winners
ADVERTISEMENT Leading European stock markets were propped up by good corporate news on Monday, as investors across the…
Is Regulatory Scrutiny and Novo Nordisk Partnership Loss Changing the Investment Case for Hims & Hers Health (HIMS)?
Hims & Hers Health is facing a securities class action lawsuit following the past termination of its partnership…